Cargando…

Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?

BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaliszewski, Krzysztof, Diakowska, Dorota, Wojtczak, Beata, Forkasiewicz, Zdzisław, Pupka, Dominika, Nowak, Łukasz, Rudnicki, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543635/
https://www.ncbi.nlm.nih.gov/pubmed/31146753
http://dx.doi.org/10.1186/s12957-019-1638-0
_version_ 1783423118247723008
author Kaliszewski, Krzysztof
Diakowska, Dorota
Wojtczak, Beata
Forkasiewicz, Zdzisław
Pupka, Dominika
Nowak, Łukasz
Rudnicki, Jerzy
author_facet Kaliszewski, Krzysztof
Diakowska, Dorota
Wojtczak, Beata
Forkasiewicz, Zdzisław
Pupka, Dominika
Nowak, Łukasz
Rudnicki, Jerzy
author_sort Kaliszewski, Krzysztof
collection PubMed
description BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis. MATERIAL AND METHODS: We performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features. RESULTS: The logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all). CONCLUSIONS: Multifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as “true cancer” and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively.
format Online
Article
Text
id pubmed-6543635
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65436352019-06-04 Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? Kaliszewski, Krzysztof Diakowska, Dorota Wojtczak, Beata Forkasiewicz, Zdzisław Pupka, Dominika Nowak, Łukasz Rudnicki, Jerzy World J Surg Oncol Research BACKGROUND: Papillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term “cancer” sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word “cancer,” the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis. MATERIAL AND METHODS: We performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features. RESULTS: The logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all). CONCLUSIONS: Multifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as “true cancer” and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively. BioMed Central 2019-05-31 /pmc/articles/PMC6543635/ /pubmed/31146753 http://dx.doi.org/10.1186/s12957-019-1638-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kaliszewski, Krzysztof
Diakowska, Dorota
Wojtczak, Beata
Forkasiewicz, Zdzisław
Pupka, Dominika
Nowak, Łukasz
Rudnicki, Jerzy
Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title_full Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title_fullStr Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title_full_unstemmed Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title_short Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
title_sort which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543635/
https://www.ncbi.nlm.nih.gov/pubmed/31146753
http://dx.doi.org/10.1186/s12957-019-1638-0
work_keys_str_mv AT kaliszewskikrzysztof whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT diakowskadorota whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT wojtczakbeata whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT forkasiewiczzdzisław whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT pupkadominika whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT nowakłukasz whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer
AT rudnickijerzy whichpapillarythyroidmicrocarcinomashouldbetreatedastruecancerandwhichasprecancer